• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆固醇含量对脂质体包裹的1-β-D-阿拉伯呋喃糖基胞嘧啶体内抗肿瘤活性和毒性的影响。

Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo.

作者信息

Ganapathi R, Krishan A, Wodinsky I, Zubrod C G, Lesko L J

出版信息

Cancer Res. 1980 Mar;40(3):630-3.

PMID:7471083
Abstract

1-beta-D-Arabinofuranosylcytosine (ara-C) was encapsulated in anionic multilamellar liposomes prepared with different lecithin: cholesterol (L:C) ratios. The chemotherapeutic activity of encapsulated ara-C was compared with comparable doses of ara-C in 0.85% saline solution (single- and multiple-dose schedules) in mice bearing L1210 (i.p.) leukemia. Maximum survival was obtained in animals given injections of ara-C (40 mg/kg) encapsulated in liposomes with a L:C ratio of 1:1. The effect of L:C ratio on survival was not pronounced in multiple-dose schedules. Multiple doses (every 4.5 hr for 3 separate injections) of 40 mg/kg with L:C ratios of 1:1 and 1:0.5 were toxic, resulting in 83 and 50% mortality, respectively, of mice by Day 7. This study shows that drug efflux and in vivo antitumor activity and toxicity of encapsulated ara-C is influenced by the cholesterol content of the liposomal lipid bilayer.

摘要

1-β-D-阿拉伯呋喃糖基胞嘧啶(阿糖胞苷)被包裹于用不同卵磷脂:胆固醇(L:C)比例制备的阴离子多层脂质体中。在携带L1210(腹腔注射)白血病的小鼠中,将包裹的阿糖胞苷的化疗活性与0.85%盐溶液中相当剂量的阿糖胞苷(单剂量和多剂量方案)进行比较。在给予注射L:C比例为1:1的脂质体包裹的阿糖胞苷(40mg/kg)的动物中获得了最大生存期。在多剂量方案中,L:C比例对生存期的影响不明显。L:C比例为1:1和1:0.5的40mg/kg多剂量(每4.5小时进行3次单独注射)具有毒性,到第7天时分别导致83%和50%的小鼠死亡。本研究表明,包裹的阿糖胞苷的药物外排、体内抗肿瘤活性和毒性受脂质体脂质双层胆固醇含量的影响。

相似文献

1
Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo.胆固醇含量对脂质体包裹的1-β-D-阿拉伯呋喃糖基胞嘧啶体内抗肿瘤活性和毒性的影响。
Cancer Res. 1980 Mar;40(3):630-3.
2
Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine.隐形脂质体:一种用于1-β-D-阿拉伯呋喃糖基胞嘧啶的改进型缓释系统。
Cancer Res. 1992 May 1;52(9):2431-9.
3
Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine.脂质体包裹的1-β-D-阿拉伯呋喃糖基胞嘧啶对小鼠中枢神经系统白血病的治疗
Cancer Res. 1989 Sep 15;49(18):5097-102.
4
Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.1-β-D-阿拉伯呋喃糖基胞嘧啶与聚谷氨酸及其衍生物的抗肿瘤活性
Cancer Res. 1984 Jan;44(1):25-30.
5
Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues.
J Pharmacol Exp Ther. 1982 Aug;222(2):324-30.
6
Role of cholesterol in enhancing the antitumor activity of cytosine arabinoside entrapped in liposomes.胆固醇在增强脂质体包裹的阿糖胞苷抗肿瘤活性中的作用。
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1923-8.
7
[Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].新型阿糖胞苷类似物4-氨基-1-β-D-阿拉伯呋喃糖基-2(1H)-嘧啶酮5'-(十八烷基磷酸钠)一水合物(YNK01)的抗肿瘤活性
Gan To Kagaku Ryoho. 1990 Aug;17(8 Pt 1):1437-45.
8
Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.硫醚磷脂的1-β-D-阿拉伯呋喃糖基胞嘧啶共轭物的制剂、稳定性及抗肿瘤活性
Cancer Res. 1990 Jul 15;50(14):4401-6.
9
Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.口服 N4-棕榈酰-1-β-D-阿拉伯呋喃糖基胞嘧啶对小鼠的抗肿瘤作用及药理学研究
Cancer Res. 1984 Jan;44(1):172-7.
10
Effects on the monocyte-macrophage system and antitumor activity against L1210 leukemia of cis-bis-cyclopentenecarboxylato-trans-R,R-1,2-diaminocyclohexane -platinum (II) encapsulated in multilamellar vesicles.多层囊泡包裹的顺式-双环戊烯羧酸酯-反式-R,R-1,2-二氨基环己烷铂(II)对单核细胞-巨噬细胞系统的影响及对L1210白血病的抗肿瘤活性
J Natl Cancer Inst. 1986 Nov;77(5):1137-43.

引用本文的文献

1
Immunological and Toxicological Considerations for the Design of Liposomes.脂质体设计的免疫学和毒理学考量
Nanomaterials (Basel). 2020 Jan 22;10(2):190. doi: 10.3390/nano10020190.
2
Clinical pharmacokinetics of cytarabine formulations.阿糖胞苷制剂的临床药代动力学。
Clin Pharmacokinet. 2002;41(10):705-18. doi: 10.2165/00003088-200241100-00002.
3
Liposomes as carriers of cancer chemotherapy. Current status and future prospects.脂质体作为癌症化疗的载体。现状与未来展望。
Drugs. 1993 Oct;46(4):618-38. doi: 10.2165/00003495-199346040-00004.
4
Increased therapeutic efficiency of a lipid-soluble alkylating agent incorporated in liposomes.脂质体包裹的脂溶性烷化剂治疗效率提高。
Br J Cancer. 1982 Jun;45(6):830-4. doi: 10.1038/bjc.1982.134.
5
Liposomally trapped AraCTP to overcome AraC resistance in a murine lymphoma in vitro.脂质体包裹的阿糖胞苷三磷酸(AraCTP)在体外克服小鼠淋巴瘤中的阿糖胞苷(AraC)耐药性。
Br J Cancer. 1982 Apr;45(4):559-64. doi: 10.1038/bjc.1982.92.
6
Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity.使用阴离子脂质体降低慢性阿霉素诱导的心脏毒性。
Proc Natl Acad Sci U S A. 1981 Mar;78(3):1873-7. doi: 10.1073/pnas.78.3.1873.
7
Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes.空白脂质体对脂质体阿糖胞苷腹膜清除率的调节作用。
Cancer Chemother Pharmacol. 1987;19(4):307-10. doi: 10.1007/BF00261478.
8
Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution.脂质体作为顺二氨二氯铂(II)的药物载体系统。II. 体内抗肿瘤活性、耐药性诱导、肾毒性及铂分布
Cancer Chemother Pharmacol. 1988;21(4):299-307. doi: 10.1007/BF00264195.